Hans-martin Schneble
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
Journal: Lancet (London, England)
Published: October 30, 2025
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
Journal: Lancet (London, England)
Published: October 30, 2025
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.
Journal: Annals of clinical and translational neurology
Published: May 23, 2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Journal: Neurology
Published: January 30, 2025
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Journal: Journal of neurology
Published: May 12, 2023
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 09, 2021
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: October 16, 2020
Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.
Journal: The Lancet. Neurology
Published: April 12, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026